IMMUNE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On February 28, 2023, shareholders holding approximately 50.58% of the outstanding common stock of Immune Therapeutics, Inc. (the "Company") executed a written consent (the "Written Consent") in lieu of a special meeting of the shareholders approving an amendment to the amended and restated articles of incorporation of the Company to change the Company's name to "Biostax Corp." (the "Articles of Amendment"). Pursuant to Rule 14c-2 of the Exchange Act of 1934, as amended, the Articles of Amendment may not become effective until at least 20 calendar days following the date on which an information statement informing shareholders of the Written Consent is first mailed to the Company's shareholders of record.

© Edgar Online, source Glimpses